TScan Therapeutics 将来の成長
Future 基準チェック /26
TScan Therapeutics is forecast to grow earnings and revenue by 2.3% and 57.2% per annum respectively. EPS is expected to grow by 17.8% per annum. Return on equity is forecast to be -68.6% in 3 years.
主要情報
2.3%
収益成長率
17.8%
EPS成長率
| Biotechs 収益成長 | 27.1% |
| 収益成長率 | 57.2% |
| 将来の株主資本利益率 | -68.6% |
| アナリストカバレッジ | Good |
| 最終更新日 | 27 Aug 2024 |
今後の成長に関する最新情報
Recent updates
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology
Aug 26Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price
Mar 23
Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?
Feb 17TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target
Mar 11TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M
Aug 10TScan Therapeutics appoints Debora Barton as Chief Medical Officer
Jul 07Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation
May 22Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?
Jan 17We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate
Oct 18業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2026 | 10 | -155 | -104 | -132 | 5 |
| 12/31/2025 | 7 | -144 | -102 | -123 | 6 |
| 12/31/2024 | 7 | -130 | -93 | -108 | 6 |
| 6/30/2024 | 12 | -104 | -75 | -71 | N/A |
| 3/31/2024 | 15 | -97 | -70 | -67 | N/A |
| 12/31/2023 | 21 | -89 | -65 | -61 | N/A |
| 9/30/2023 | 17 | -88 | -58 | -54 | N/A |
| 6/30/2023 | 16 | -82 | -82 | -79 | N/A |
| 3/31/2023 | 17 | -73 | -74 | -70 | N/A |
| 12/31/2022 | 14 | -66 | -71 | -67 | N/A |
| 9/30/2022 | 13 | -62 | -70 | -65 | N/A |
| 6/30/2022 | 12 | -61 | -67 | -62 | N/A |
| 3/31/2022 | 11 | -57 | -66 | -59 | N/A |
| 12/31/2021 | 10 | -49 | -59 | -49 | N/A |
| 9/30/2021 | 8 | -42 | -51 | -42 | N/A |
| 6/30/2021 | 6 | -34 | -43 | -34 | N/A |
| 3/31/2021 | 3 | -29 | -14 | -8 | N/A |
| 12/31/2020 | 1 | -26 | -7 | -3 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: TCRX is forecast to remain unprofitable over the next 3 years.
収益対市場: TCRX is forecast to remain unprofitable over the next 3 years.
高成長収益: TCRX is forecast to remain unprofitable over the next 3 years.
収益対市場: TCRX's revenue (57.2% per year) is forecast to grow faster than the US market (8.9% per year).
高い収益成長: TCRX's revenue (57.2% per year) is forecast to grow faster than 20% per year.
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: TCRX is forecast to be unprofitable in 3 years.